home / stock / ivevf / ivevf news

IVEVF News and Press, Inventiva SA From 09/28/23

Stock Information
Company Name: Inventiva SA
Stock Symbol: IVEVF
Market: OTC
Website: inventivapharma.com
Menu
IVEVF IVEVF Quote IVEVF Short IVEVF News IVEVF Articles IVEVF Message Board
Get IVEVF Alerts

News, Short Squeeze, Breakout and More Instantly...
IVEVF - Inventiva reports its 2023 first-half financial results and provides a corporate update

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million 1 , and long-term deposit at €9.3 million 2 , as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivel R...
IVEVF - Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $ 231 million in clinical, regulatory and ...

IVEVF - Inventiva announces a financing of approximately Euro35.7 million from new and existing investors, consisting of a Euro30.6 million reserved capital increase and a Euro5.1 million issuance of royalty certificates

Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment o...

IVEVF - Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million 2 , and long-term deposit at €9.3 million 3 as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively Re...
IVEVF - Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million 2 , and long-term deposit at €9.3 million 3 as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively Re...

IVEVF - Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

Daix (France), Long Island City (New York, United States) , June 2 4 , 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic stea...

IVEVF - Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy ( 1 H-MRS) following 24 weeks of treatment in patients with nonalcoholic fatty liver disease (NAFLD). A significantly higher proportion...
IVEVF - Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients  

Daix (France), Long Island City (New York, United States) / Paris (France) and Waltham (United States), June 8, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small mol...

IVEVF - Inventiva announces five scientific presentations at the EASL International Liver Congress(TM) 2023

Five poster presentations showing : the correlation between the improvement of hepatic steatosis and a robust increase in adiponectin levels, improvement in lipid profile and glycemic control in patients with non-cirrhotic NASH treated with lanifibranor. the Early improvement in ALT or AS...

IVEVF - Results of the votes of the Combined Shareholders' General Meeting of May 25, 2023

Daix (France), Long Island City (New York, United States), May 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other...
Previous 10 Next 10